No domashniaia ptica porody kyr poroda kyr rysskaia hohlataia opisanie soderjanie kormlenie yhod i razvedenie

News press releases us food and drug administration approves gileads sovaldi sofosbuvir for the trea

news press releases us food and drug administration approves gileads sovaldi sofosbuvir for the trea

US Food and Drug Administration approves Gilead's Sovaldi (sofosbuvir) for the treatment of chronic hepatitis C [ press release ]. December 6, www. gilead. com/ news / press - releases //12/ us - food -and- drug -. Sovaldi (sofosbuvir) is used to treat chronic hepatitis C virus (HCV) infection. that the U.S. Food and Drug Administration (FDA) has approved a supplemental To support these patients and their families, Gilead's U.S. Support Path® This press release includes forward-looking statements within the. Harvoni and Sovaldi were previously approved to treat HCV in adults. FDA News Release Release. The U.S. Food and Drug Administration today approved for Sovaldi (sofosbuvir) and Harvoni (ledipasvir and sofosbuvir) to treat hepatitis Harvoni and Sovaldi are marketed by Gilead Sciences, Inc.

News press releases us food and drug administration approves gileads sovaldi sofosbuvir for the trea - top

Gilead has operations in more than 30 countries worldwide, with headquarters in Foster City, California. Lawitz E, Mangia A, Wyles D, et al. The acquisition brings drug candidate CYTan orally-administered, once-daily, selective inhibitor of the Janus kinase JAK family, specifically JAK1 and JAK2, into Gilead's oncology pipeline. Supplemental approval of sofosbuvir plus ribavirin was supported by data from Gilead's Studyan open-label trial of 50 adolescents age with or without cirrhosis. news press releases us food and drug administration approves gileads sovaldi sofosbuvir for the trea

Facebooktwittergoogle_plusredditpinterestlinkedinmail